Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Karyopharm Therapeutics Inc. - Common Stock
(NQ:
KPTI
)
1.635
+0.035 (+2.19%)
Streaming Delayed Price
Updated: 10:35 AM EDT, Sep 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Karyopharm Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Let's have a look at the top gainers and losers in the middle of the day of today's session.
↗
September 11, 2026
Via
Chartmill
Traders are paying attention to the gapping stocks in Friday's session.
↗
September 11, 2026
Via
Chartmill
Which stocks are moving before the opening bell on Friday?
↗
September 11, 2026
Via
Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
August 25, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Karyopharm Therapeutics Inc (NASDAQ:KPTI) Posts Q1 Beat and Highlights ASCO Presentation, Shares Surge 7%
↗
May 14, 2026
Via
Chartmill
Karyopharm Therapeutics Inc (NASDAQ:KPTI) Reports Q4 Revenue Miss and Wider Loss, Stock Falls in Pre-Market
↗
February 12, 2026
Via
Chartmill
Earnings Scheduled For November 3, 2025
↗
November 03, 2025
Via
Benzinga
Karyopharm Therapeutics Earnings Preview
↗
October 31, 2025
Via
Benzinga
Karyopharm (KPTI) Q2 2026 Earnings Call Transcript
↗
August 20, 2026
Biotech pivots to hematology after endometrial cancer setback, faces debt deadline.
Via
The Motley Fool
Topics
Earnings
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
August 18, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Karyopharm Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript
↗
August 13, 2026
Karyopharm Therapeutics (NASDAQ:KPTI) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is...
Via
Benzinga
Topics
Earnings
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
August 11, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
August 04, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Top movers in Friday's session
↗
July 31, 2026
Via
Chartmill
Top stock movements in today's session.
↗
July 31, 2026
Via
Chartmill
Gapping stocks in Friday's session
↗
July 31, 2026
Via
Chartmill
Friday's pre-market session: top gainers and losers
↗
July 31, 2026
Via
Chartmill
Thursday's after hours session: top gainers and losers
↗
July 30, 2026
Via
Chartmill
Which stocks are moving on Monday?
↗
July 20, 2026
Via
Chartmill
Karyopharm Therapeutics Spotlights Selinexor Milestones, ASCO Data and Cancer Trial Readouts
↗
May 26, 2026
Karyopharm Therapeutics (NASDAQ:KPTI) executives used an H.C. Wainwright BioConnect Conference appearance to highlight upcoming clinical and regulatory milestones for selinexor, the company’s oral...
Via
MarketBeat
Karyopharm Therapeutics Teases ASCO SENTRY Data as FDA Path Comes Into Focus
↗
May 26, 2026
Karyopharm Therapeutics (NASDAQ:KPTI) executives said the company expects to provide a fuller presentation of its Phase 3 SENTRY trial data for selinexor in myelofibrosis at the upcoming ASCO...
Via
MarketBeat
Karyopharm (KPTI) Q1 2026 Earnings Transcript
↗
May 14, 2026
Karyopharm (KPTI) Q1 2026 Earnings Transcript
Via
The Motley Fool
Karyopharm Therapeutics Q1 Earnings Call Highlights
↗
May 14, 2026
Karyopharm Therapeutics (NASDAQ:KPTI) said it entered 2026 with several near-term clinical and regulatory catalysts, led by new Phase 3 data in myelofibrosis and an expected midyear readout in...
Via
MarketBeat
Topics
Earnings
Karyopharm (KPTI) Q2 2025 Earnings Transcript
↗
May 04, 2026
Karyopharm (KPTI) Q2 2025 Earnings Transcript
Via
The Motley Fool
Karyopharm (KPTI) Q1 2025 Earnings Transcript
↗
May 04, 2026
Karyopharm (KPTI) Q1 2025 Earnings Transcript
Via
The Motley Fool
Registration Momentum Builds Across the Oncology Pipeline
February 17, 2026
Issued on behalf of Oncolytics Biotech Inc.
From
USA News Group
Via
GlobeNewswire
Karyopharm (KPTI) Q4 2025 Earnings Call Transcript
↗
February 12, 2026
Karyopharm (KPTI) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Derivatives
Earnings
Karyopharm Therapeutics Inc (NASDAQ:KPTI) Reports Q3 2025 Revenue Beat and Earnings Miss
↗
November 03, 2025
Karyopharm (KPTI) Q3 2025 results show a revenue beat but an earnings miss. The stock rose pre-market as investors focus on XPOVIO sales growth and key Phase 3 data due in 2026.
Via
Chartmill
Topics
Earnings
This Palo Alto Networks Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
↗
October 13, 2025
Via
Benzinga
Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026
↗
October 08, 2025
Karyopharm secures $100 million financing, extends cash runway into 2026, projects $42 million–$44 million Q3 revenue, and advances Phase 3 selinexor trial.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
